Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.68 |
| ▸ | THRB | P10828 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207139 | 0.92 | PKM (0.58) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL7727868 | 0.85 | PKM (0.70) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL7024490 | 0.84 | PKM (0.68) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL896025 | 0.83 | PKM (0.46) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL7025943 | 0.83 | PKM (0.66) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL14593304 | 0.81 | PKM (0.79) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL14503012 | 0.81 | PKM (0.78) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL10207140 | 0.80 | PKM (0.51) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL16309672 | 0.80 | ATM (0.49) | PKMTHRBHTTMAPTMEN1 | |
| SCHEMBL8499870 | 0.78 | PKM (0.79) | PKMTHRBHTTMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164186-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164186-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20140255991-A1 | OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-09-11 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120077228-A1 | OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-03-29 | — | — | US | disclosed |
| US-20100184193-A1 | OVEREXPRESSION OF AMINOACYL-tRNA SYNTHETASES FOR EFFICIENT PRODUCTION OF ENGINEERED PROTEINS CONTAINING AMINO ACID ANALOGUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7723070-B2 | Adding an desired amino acid analog to a medium containing a host cell with a vector coding for aminoacyl-tRNA synthetase and a vector coding for the polypeptide of interest; and growing the cell to produce the modified polypeptide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080160609-A1 | Dihydrofolate reductase; site directed mutagenesis; point mutations; auxotroph host cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080026422-A1 | Adding an desired amino acid analog to a medium containing a host cell with a vector coding for aminoacyl-tRNA synthetase and a vector coding for the polypeptide of interest; and growing the cell to produce the modified polypeptide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-01-31 | — | — | US | disclosed |
| US-7198915-B2 | Preparing modified/artificial polypeptides; mimetics | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040058415-A1 | Preparing modified/artificial polypeptides; mimetics | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-03-25 | — | — | US | disclosed |
| US-6586207-B2 | Host cell is a methionine auxotroph; methionine-tRNA synthetase overexpressed in presence of analogues and absence of methionine; protein is modified dihydrofolate reductase | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-07-01 | — | — | US | disclosed |
| US-20020042097-A1 | Host cell is a methionine auxotroph; methionine-tRNA synthetase overexpressed in presence of analogues and absence of methionine; protein is modified dihydrofolate reductase | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | PKM 909/4885THRB 2176/4885HTT 4239/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | PKM 909/4885THRB 2176/4885HTT 4239/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | PKM 909/4885THRB 2176/4885HTT 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.